Literature DB >> 3105631

Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours.

J W Hetherington, D W Newling, M R Robinson, P H Smith, R S Adib, P Whelan.   

Abstract

Forty-three patients with recurrent multiple superficial bladder tumours (Tis, Ta and Tl) were treated with Mitomycin C 20 mg in 20 ml water intravesically weekly for 8 to 12 weeks, and monthly instillations were continued for 5 to 6 months. Residual tumour was resected at 12 weeks, at which time 40 patients (93%) showed a response to treatment. A complete response was seen in 24 (56%) and 16 (37%) showed a partial response. After a follow-up of 12 to 48 months (median 19), 19 of 33 evaluable patients (58%) have shown tumour recurrence. Invasive tumour has developed in seven (17%) and transitional cell tumours of the ureter in two of those patients who showed an initial response to treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105631     DOI: 10.1111/j.1464-410x.1987.tb04614.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  2 in total

1.  Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.

Authors:  R Minervini; R Felipetto; L Viganò; M Cecchi
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

2.  Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.

Authors:  S N Datta; R Allman; C Loh; M Mason; P N Matthews
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.